HSAQ SEC filings, in plain English
Everything Health Sciences Acquisitions Corp 2 has filed with the SEC that we hold — 40 filings, newest first, 4 with a plain-English summary of what changed and why it matters. Every row links to the primary document on EDGAR, so you can check the source rather than trust us.
The feed
live EDGAR captureNew filings appear here within minutes of hitting EDGAR; summaries follow once the pipeline has read them.
What changed: The 10-Q filed under Commission file number 001-39421 is that of Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) for the quarter ended June 30, 2026, with 60,105,049 shares outstanding as of August 6, 2026. Why it matters: Enrollment completion in the two named trials and the availability of further borrowing under existing facilities are the two variables the company itself puts first. The condensed consolidated financial statements are not in the portion read here, so no cash, debt or trial-timing figure is attributed.
What changed: Item 5.07: Orchestra BioMed Holdings held its 2026 annual meeting on June 23, 2026, with 49,053,298 of 59,880,715 shares entitled to vote represented. Stockholders elected three Class III directors: David P. Hochman with 39,724,691 for and 97,018 withheld, Darren R. Sherman with 39,544,240 for and 277,469 withheld, and Eric S. Fain with 37,810,358 for and 2,011,351 withheld, each with 9,231,589 broker non-votes. Ernst & Young was ratified as auditor 49,039,578 for and 13,692 against, and the 2026 equity incentive plan was approved 39,639,592 for and 150,243 against. Why it matters: The vote is a routine annual meeting with no contested outcomes, but two details are worth noting for holders of a company that came public through a SPAC: director Eric S. Fain drew 2,011,351 withheld votes, more than twenty times the opposition to the other nominees, which points to a specific shareholder concern; and a new equity incentive plan was approved, which authorises further share issuance and therefore dilution. Nothing here bears on cash, revenue or operating performance.
What changed: Orchestra BioMed Holdings, Inc. supplemented its April 29, 2026 definitive proxy statement for the Annual Meeting of Stockholders to be held June 23, 2026. The supplement exists to furnish Appendix A, the full text of the Orchestra BioMed Holdings, Inc. 2026 Employee Stock Purchase Plan, which was inadvertently omitted from the definitive proxy statement. The company states that all material information relating to the ESPP was included in the definitive proxy statement, and that the plan was adopted by the board of directors on April 22, 2026. Why it matters: The plan text is now on the record with its limits: a maximum of 750,000 shares of common stock issuable, shared across a Section 423 component and a non-423 component, with shares under purchase rights that terminate unexercised returning to the pool. The board, or a committee to which it delegates, administers the plan, may adopt sub-plans for employees outside the United States, and may amend, suspend or terminate the plan. The plan's signature block leaves the stockholder-approval date blank for June 2026. Nothing else in the proxy statement changes.
combination deadlinenothing moved · 1 with no prior record of ours
- Combination deadline
- 2023-01-26not matched in this filing
Read from stored SEC filing text by a regex — no model is involved — and each side links to the filing it came from. “Not previously extracted” is a statement about our record, not about the company: the clause may be present in wording we do not match.
What changed: Orchestra BioMed Holdings, Inc., the successor to Health Sciences Acquisitions Corp 2, called its 2026 annual meeting for Tuesday, June 23, 2026 at 12:00 p.m. Eastern Time, held virtually, with a record date of April 28, 2026 fixed by the board. Materials including the 2025 Annual Report on Form 10-K are available free of charge at proxyvote.com. The compensation section discloses a clawback on Mr. Why it matters: Routine post-de-SPAC annual governance - the HSAQ 2 trust was released at closing, so no redemption right, deadline or per-share floor remains for legacy SPAC holders. The only forward-looking item is the May 15, 2026 bonus repayment cliff, which is a retention lock expiring within weeks of the meeting and therefore a date to watch for executive departures.
What changed vs 2025-04-30going concern RESOLVEDgoing-concern doubt1 moved
- Going-concern doubt
- statednot stated
SpacBrain reads this as the substantial-doubt sentence is in the previous filing and not in this one.
Read from stored SEC filing text by a regex — no model is involved — and each side links to the filing it came from. “Not previously extracted” is a statement about our record, not about the company: the clause may be present in wording we do not match.
In plain English
Redemption deadlinethe last day to hand shares back for cash
Set by the filing that calls the meeting. Tender after it and the company is under no obligation to pay you the trust value.
Cash in trust / trust per sharethe cash the company is holding for each public share
Filed quarterly in the 10-Q's XBRL. It earns interest between filings, so the figure on a given day is slightly higher than the last filed one — where we show that we label it an estimate.
Accession numberthe SEC's unique id for one filing
Every figure on this page carries the accession of the filing that states it, so you can open the primary document rather than trust us.